Thursday, May 26, 2016



Soy un nuevo usuario

Olvidé mi contraseña

Entrada usuarios

Lógica Matemáticas Astronomía y Astrofísica Física Química Ciencias de la Vida
Ciencias de la Tierra y Espacio Ciencias Agrarias Ciencias Médicas Ciencias Tecnológicas Antropología Demografía
Ciencias Económicas Geografía Historia Ciencias Jurídicas y Derecho Lingüística Pedagogía
Ciencia Política Psicología Artes y Letras Sociología Ética Filosofía

Novel Therapies for Aggressive B-Cell Lymphoma

1) La descarga del recurso depende de la página de origen
2) Para poder descargar el recurso, es necesario ser usuario
    registrado en Universia

  Descargar recurso

Detalles del recurso

Pertenece a: PubMed Central (PMC3 - NLM DTD)  

Descripción: Aggressive B-cell lymphoma (BCL) comprises a heterogeneous group of malignancies, including diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma, and mantle cell lymphoma (MCL). DLBCL, with its 3 subtypes, is the most common type of lymphoma. Advances in chemoimmunotherapy have substantially improved disease control. However, depending on the subtype, patients with DLBCL still exhibit substantially different survival rates. In MCL, a mature B-cell lymphoma, the addition of rituximab to conventional chemotherapy regimens has increased response rates, but not survival. Burkitt lymphoma, the most aggressive BCL, is characterized by a high proliferative index and requires more intensive chemotherapy regimens than DLBCL. Hence, there is a need for more effective therapies for all three diseases. Increased understanding of the molecular features of aggressive BCL has led to the development of a range of novel therapies, many of which target the tumor in a tailored manner and are summarized in this paper.

Autor(es): Foon, Kenneth A. -  Takeshita, Kenichi -  Zinzani, Pier L. - 

Id.: 55223208

Idioma: English  - 

Versión: 1.0

Estado: Final

Palabras claveReview Article - 

Tipo de recurso: Text  - 

Tipo de Interactividad: Expositivo

Nivel de Interactividad: muy bajo

Audiencia: Estudiante  -  Profesor  -  Autor  - 

Estructura: Atomic

Coste: no

Copyright: sí

Requerimientos técnicos:  Browser: Any - 

Fecha de contribución: 27-abr-2012



Otros recursos del mismo autor(es)

  1. A Phase 2 Study of Belinostat (PXD101) in Patients with Relapsed or Refractory Acute Myloid Leukemia or Patients Over 60 with Newly-Diagnosed Acute Myloid Leukemia: A California Cancer Consortium Study We performed a phase II study of belinostat in patients with acute myloid leukemia (AML). In this op...
  2. The B lineage transcription factor E2A regulates apoptosis in chronic lymphocytic leukemia (CLL) cells Chronic lymphocytic leukemia (CLL) is a common malignancy characterized by the accumulation of B lym...
  3. A phase I trial of recombinant gamma interferon in patients with cancer A total of 11 patients were treated on an escalating, single dose trial of recombinant gamma interfe...
  4. Biological therapy of cancer Interferons and monoclonal antibodies are among the most promising biological approaches to cancer t...
  5. Immunologic classification of lymphoma and lymphoid leukemia Important insights into lymphocyte differentiation and the cellular origins of lymphoma and lymphoid...

Otros recursos de la misma colección

  1. Effect of the putative lithium mimetic ebselen on brain myo-inositol, sleep and emotional processing in humans Lithium remains the gold standard in treating bipolar disorder but has unwanted toxicity and side ef...
  2. Nuclear Hormone Receptor LXRα Inhibits Adipocyte Differentiation of Mesenchymal Stem Cells with Wnt/beta-catenin Signaling Nuclear hormone receptor liver X receptor-alpha (LXRα) plays a vital role in cholesterol homeostasis...
  3. Multiplexed analysis of chromosome conformation at vastly improved sensitivity Since methods for analysing chromosome conformation in mammalian cells are either low resolution or ...
  4. Conserved Molecular Interactions in Centriole-to-Centrosome Conversion Centrioles are required to assemble centrosomes for cell division and cilia for motility and signali...
  5. Group 3 innate lymphoid cells continuously require the transcription factor GATA3 after commitment The transcription factor GATA3 is indispensable for the development of all interleukin-7 receptor α ...

Valoración de los usuarios

No hay ninguna valoración para este recurso.Sea el primero en valorar este recurso.

Busque un recurso